Diagnostic Product Commercialization
IV Bioholdings – THE CLIENT
Founded in 2018, IVBH is dedicated to revolutionizing the way we detect and diagnose diseases. An emerging leader in liquid biopsy technology, IVBH specializes in early detection precision diagnostics. Their goal is to create highly accurate, affordable, and accessible diagnostic solutions that can detect disease in its earliest stages (e.g., stage 0-II) and also eliminate unnecessary procedures that are invasive, risky, expensive, and stressful.
IVBH’s flagship liquid biopsy programs are focused on three specific diseases: breast cancer, lung cancer, and non-alcoholic fatty liver disease (NAFLD). They are working tirelessly to develop diagnostic tests that can detect these diseases at an early stage when treatment is most effective. Their liquid biopsy technology is a non-invasive alternative to traditional diagnostic methods and aims to provide highly accurate results with minimal discomfort for the patient.
IVBH is committed to improving the lives of people all around the world by providing cutting-edge diagnostic solutions. Their innovative approach to early detection precision diagnostics is part of a revolution that will change the face of healthcare. IVBH is working towards a future where people can live longer, healthier lives without the fear of invasive, risky, and expensive procedures.
Like any company at the cutting edge of precision medicine, IVBH faced a number of challenges that they had to overcome.
Legacy data: IVBH had amassed a large volume of legacy data during the biomarker discovery phase. They needed access to powerful, secure analysis tools and support from data science experts to fully exploit the data sets and create visualizations that would help present their findings to prospective partners.
Identification of independent validation data sets: IVBH needed expert support to source and integrate relevant new datasets, to further support the effectiveness of their liquid biopsy technology to potential partners through external validation studies.
Reproducibility: This is a common problem in the biomarker development field. It can be difficult to prove the validity of a new biomarker or molecular signature without robust data science support.
Lack of in-house Data Science expertise: To further develop and optimize their technology, they required a team of experts who could help to analyze the data and select and then apply the best methodologies to refine their signatures.
Investment: To build the business case for further investment, IVBH needed to add robustness to their workflows and demonstrate that their technology is viable. It required them to produce visualizations of their data that efficiently demonstrated the power and potential of their technology to non-specialist and specialist audiences.
The team at Sonrai was excited to help IVBH to overcome these challenges and meet its objectives.
Unlock the full potential of their data: Sonrai’s AI data analytics platform flagged the important features of their data set and allowed IVBH to focus on the most relevant information. This made it much easier for IVBH to extract meaningful insights and enabled them to make data-driven decisions.
Vital data science support: Sonrai provided IVBH with vital data science support, helping them to analyze, interpret and share discoveries of their data. With the help of Sonrai’s team of experts, IVBH was able to get a deeper understanding of their data and make sense of the complex information they had collected.
AI and ML: Sonrai incorporated AI and ML applications to refine gene signatures – crucial for detecting diseases at an early stage. This helped IVBH to improve the accuracy of their diagnostic tests and make them more effective in detecting diseases.
Multidisciplinary collaboration: Sonrai collaborated directly with IVBH’s lab partner, P4 Diagnostix, enabling them to process and interrogate new data more effectively and share resources and expertise. This helped IVBH to establish a highly efficient bridge between its research and development and clinical workflows.
Clinical assay development experience: Sonrai biomarker experts helped IVBH create robust study designs for the validation of their biomarkers, creating greater confidence in the resultant data.
Dedicated Project Management: Sonrai assigned an experienced project manager to the program which helped IVBH to stay on track and overcome any challenges that they faced during their research and development.
Closer to Commercialisation
IVBH are already in discussions to commercialize their product.
Enhanced Investment Case
By supporting IVBH to validate its biomarkers and technology, Sonrai has helped build the IVBH investment opportunity.
Data Science Savings
IVBH made considerable savings in working with Sonrai’s biologists, data scientists, bioinformaticians, software engineers, and imaging and diagnostic experts.